Cantor Fitzgerald Reiterates a Buy Rating on TherapeuticsMD (TXMD)

By Austin Angelo

Cantor Fitzgerald analyst Louise Chen reiterated a Buy rating on TherapeuticsMD (TXMDResearch Report) today and set a price target of $27. The company’s shares closed on Friday at $5.11.

Chen observed:

“We reiterate our OW rating. The execution behind the launches of Annovera is underappreciated, in our view, and we think peak sales could exceed modest expectations for three drugs that target large unmet needs. Valuation Summary We use a blend of EV/EBITDA and DCF analysis to arrive at our 12-month PT of $27. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of EV/EBITDA and DCF analysis to arrive at our 12-month PT of $27.”

According to TipRanks.com, Chen is a 4-star analyst with an average return of 4.7% and a 35.1% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Amneal Pharmaceuticals Inc, and Aridis Pharmaceuticals Inc.

TherapeuticsMD has an analyst consensus of Strong Buy, with a price target consensus of $19.

See today’s analyst top recommended stocks >>

The company has a one-year high of $7.66 and a one-year low of $3.51. Currently, TherapeuticsMD has an average volume of 3.33M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.